戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              S. sonnei infections increased from 8.3 (historical peri
2                                              S. sonnei is an emerging drug-resistant threat.
3                                              S. sonnei is divided into five monophyletic lineages, ye
4     Applying this approach to analyse >4,000 S. sonnei isolates sequenced in public health labs in th
5 table candidate for vaccine construction, 16 S. sonnei strains were screened for stability of the vir
6                   Here we analyse nearly 400 S. sonnei whole genome sequences from both endemic and n
7 with Ty21a-AR-Ss produced antibodies against S. sonnei and S.
8 overy of human monoclonal antibodies against S. sonnei, a species whose prevalence is constantly incr
9 ectrum Shigella vaccine must protect against S. sonnei and 15 S. flexneri serotypes/subserotypes.
10 p a bivalent oral vaccine to protect against S. sonnei shigellosis and typhoid fever.
11 iveness of Ty21a-AR-Ss in protecting against S. sonnei shigellosis and typhoid fever, as compared wit
12  numerically lower compared to those against S. sonnei and S. flexneri 2a.
13 ution of novel antimicrobial resistant (AMR) S. sonnei variants after introduction into Vietnam.
14 cide vector pCVD442, was used to generate an S. sonnei virG deletion strain, WRSS1, which was invasiv
15  of shigellosis that both S. flexneri 5a and S. sonnei induced local hemorrhages and we demonstrated
16 se isolates; S. flexneri comprised 65.9% and S. sonnei 23.7%.
17 asmid transfer between commensal E. coli and S. sonnei.
18 on a pathogenicity island in S. flexneri and S. sonnei and in a different chromosomal location in S.
19 o protect mice against Shigella flexneri and S. sonnei in the lethal pulmonary challenge.
20 e study period, diagnoses of S. flexneri and S. sonnei infections were most common in men with no his
21 d susceptibility to azithromycin, as well as S. sonnei, and supports the utility of susceptibility te
22 ltidrug-resistant plasmid isolated from both S. sonnei and E. coli in the gut of a single child.
23 after injection 2, 85.7%; 88.9%) followed by S. sonnei (ELISA after injection 1, 77.6%; after injecti
24 nd a high prevalence of AMR commensals, cipR S. sonnei may be propelled towards pan-resistance by adh
25                       The potential for cipR S. sonnei to develop resistance to alternative second-li
26                           We found that cipR S. sonnei displaced the resident ciprofloxacin-susceptib
27 among the 24 patients with culture-confirmed S. sonnei infection.
28 tion in induction of inflammatory cytokines (S. sonnei DeltahtrB, 800-fold; DeltamsbB mutants, 300-fo
29 ies generated in response to an experimental S. sonnei vaccine followed by a controlled human infecti
30 e to create Ty21a-Ss, which stably expresses S. sonnei form I O antigen.
31 h of the four Shigella species: S. flexneri, S. sonnei, S. boydii, and S. dysenteriae.
32                        Treatment options for S. sonnei are dwindling due to resistance to several key
33  genomic framework and genotyping scheme for S. sonnei to efficiently identify genotype and resistanc
34 equencing (WGS) is increasingly utilised for S. sonnei outbreak investigation and surveillance, but c
35  A quadrivalent vaccine with O antigens from S. sonnei, S. flexneri 2a, S. flexneri 3a, and S. flexne
36 ial cells and conferred full protection from S. sonnei infection in vivo.
37  than Shigella sonnei (58% vs 36%); however, S. sonnei constituted most of the isolates with decrease
38 esent in pINV from S. flexneri but absent in S. sonnei pINV.
39 etic analysis showed this recent increase in S. sonnei infections was attributed to a novel clade tha
40 cholate negatively regulates IcsA and MAM in S. sonnei resulting in reduction in attachment and invas
41                      Multidrug resistance in S. sonnei is common including against World Health Organ
42 reasing rates of ciprofloxacin resistance in S. sonnei, in addition to plasmid-mediated azithromycin
43        Typhi, and survived lethal intranasal S. sonnei challenge.
44 a high-resolution melting (HRM) assay, major S. sonnei lineages/sublineages can be identified as defi
45 e associated with the 3.6.1.1.2 clone of MDR S. sonnei in PEH could be a result of underlying vulnera
46                      A dominant clone of MDR S. sonnei, 3.6.1.1.2 (CipR.MSM5), emerged with resistanc
47 ved a high rate of multidrug-resistant (MDR) S. sonnei bacteremia among persons experiencing homeless
48                    Here, we describe a novel S. sonnei adhesin, SSO1327 which is a multivalent adhesi
49 een 2015 and 2016 and the number of cases of S. sonnei infection increasing from 2017.
50 is and PFGE allow better characterization of S. sonnei transmission patterns of "endemic" strains and
51 lence profiles, while the four sub-Clades of S. sonnei varied in virulence plasmid retention.
52 emiology, clinical outcomes, and genomics of S. sonnei infections over time.
53      Here, we report a phylogenetic group of S. sonnei with extensive drug resistance, including a co
54     Outbreak-related and control isolates of S. sonnei from each city were subtyped by pulsed-field g
55  provide an overview of current knowledge of S. sonnei, highlighting recent insights into this global
56    Our analysis was limited by the number of S. sonnei sequences available from diverse geographical
57 idemiology, microbiology and pathogenesis of S. sonnei.
58 iological trends and increasing relevance of S. sonnei.
59                   Hence, a single subtype of S. sonnei caused an international outbreak involving 8 t
60 findings link the epidemiological success of S. sonnei to heightened virulence and stress tolerance,
61 r sociodemographic variables and preexisting S. sonnei serum IgA antibodies (adjusted OR, 0.37; 95% C
62 n-antitoxin system, CcdAB, from pINV reduces S. sonnei plasmid stability outside the host, reflecting
63 rvoir populations of antimicrobial-resistant S. sonnei.
64 continental surge of ciprofloxacin-resistant S. sonnei and is capable of establishing endemic transmi
65             However, ciprofloxacin-resistant S. sonnei are being increasingly isolated in Asia and sp
66 y, we found that all ciprofloxacin-resistant S. sonnei formed a single clade within a Central Asian e
67 f 60 contemporaneous ciprofloxacin-resistant S. sonnei isolated in four countries within Asia (Vietna
68 ernational spread of ciprofloxacin-resistant S. sonnei.
69 tamase producing, extensively drug resistant S. sonnei was reported in the United Kingdom.
70 e emergence of the fluoroquinolone-resistant S. sonnei population around 2007 in South Asia.
71  recently emergent fluoroquinolone-resistant S. sonnei.
72  intercontinental spread of highly-resistant S. sonnei clones and demonstrating the genomic framework
73 fluoroquinolone exposure in vitro, resistant S. sonnei develops further intolerance to the antimicrob
74 upied by the O-antigen in the case of smooth S. sonnei phase I.
75                             A stable strain, S. sonnei Mosely, was selected for further work.
76 s and find that epidemiologically successful S. sonnei harbour fewer genes encoding putative immunoge
77             This study has demonstrated that S. sonnei phylogeny can be accurately defined with limit
78 parison among major subgroups, we found that S. sonnei contributes >=6-fold more disease than other S
79                           Our data show that S. sonnei was introduced into Vietnam in the 1980s and h
80                                          The S. sonnei MAM mediates intimate attachment to host cells
81  levels induced in young outbred mice by the S. sonnei O-SPC conjugates were significantly higher the
82  600-fold reduced ability, and GMMA from the S. sonnei DeltahtrB mutant showed a 60,000-fold reduced
83 lsed-field gel electrophoresis (PFGE) of the S. sonnei isolates identified 11 and 4 patterns, respect
84 nal Kdo residues at the reducing ends of the S. sonnei saccharides and aminooxy linkers bound to BSA
85                         We recombineered the S. sonnei form I O-antigen gene cluster into the Ty21a c
86                   Attempts to synthesize the S. sonnei O-SP based oligosaccharides were not successfu
87 ce-encoding region of pINV, we show that the S. sonnei plasmid is less stable than that of S. flexner
88 cern, 147/159 (92.4%) of isolates within the S. sonnei MSM-associated lineage harbored mutations asso
89 gellosis and shift from sexually transmitted S. sonnei infections in MSM to likely environmental tran
90 , we sequenced the genomes of 263 Vietnamese S. sonnei isolated over 15 y.
91 d immune protection in mice against virulent S. sonnei challenge, thereby supporting the promise of l
92 ngestion of contaminated food and/or water), S. sonnei predominates in wealthy countries and is mainl
93  poor clinical outcomes were associated with S. sonnei.
94 amate decarboxylase systems coexpressed with S. sonnei form I O-antigen gene.
95 r of antimicrobial-resistant pathogens, with S. sonnei acting as a tractable model for studying how a
96                                Patients with S. sonnei and a low MIC (4 ug/mL) still had elevated rat
97  A retrospective review of 163 patients with S. sonnei infections was undertaken from 2015 to 2022.
98 i-infected subjects among case patients with S. sonnei shigellosis was also significantly lower than
99 show that resistance to ciprofloxacin within S. sonnei may be globally attributed to a single clonal
100 ogic failure as a stool culture that yielded S. sonnei after treatment finished.